BioSpace News Archive

Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report first quarter 2022 financial results on Thursday, May 12, 2022.

Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it will issue its financial results press release for the fourth quarter ended December 31, 2021, on Friday, April 29, 2022.

ProMIS Neurosciences, Inc. announced new milestones in potential therapeutic approaches for ALS.

Rapid Therapeutics Science Laboratories (OTC: RTSL) (“Rapid Therapeutic’’ or the “Company”), a growth-oriented aerosol manufacturing company focused on natural relief innovations through trusted aerosol delivery, announces today that its senior management and senior scientists have been invited to attend the Respiratory Drug Delivery (RDD) 2022 Conference.

BeyondSpring Inc. announced three poster presentations relating to lead asset plinabulin at the American Society of Clinical Oncology Annual Meeting being held June 3-7, 2022, in Chicago, Illinois and virtually.

Galmed Pharmaceuticals Ltd. announced interim results from the Open-Label Part of the ARMOR study showing fibrosis improvement with Aramchol using multimodality histological assessment.

Concert Pharmaceuticals, Inc. announced that it will report its financial results for the first quarter of 2022, on Thursday, May 5, 2022, before the U.S. financial markets open.

Optum Rx, the pharmacy care services business of UnitedHealth Group, is donating 5,000 at-home COVID-19 rapid antigen self-tests to increase access to COVID-19 testing and support for underserved communities across Chicago.

Baxter International Inc., a global medtech leader, reported results for the first quarter of 2022.

April 28, 2022 11:00 UTC ULTOMIRIS ® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis First and only long-acting C5 complement inhibitor to demonstrate clinical improvement in patients with generalized myasthenia gravis ULTOMIRIS showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks WILMINGTON, Del.--( BUSINESS WIRE )-- ULTOMIRIS ® (rav